Heterologous vaccine regimens against COVID-19

Talita Duarte-Salles; Daniel Prieto-Alhambra; D. (Dani) Prieto Alhambra

doi:10.1016/s0140-6736(21)01442-2

Heterologous vaccine regimens against COVID-19

Talita Duarte-Salles, Daniel Prieto-Alhambra, D. (Dani) Prieto Alhambra

Medical Informatics

Research output: Contribution to journal › Comment/Letter to the editor › Popular

32 Citations (Scopus)

Original language	English
Pages (from-to)	94-95
Number of pages	2
Journal	The Lancet
Volume	398
Issue number	10295
DOIs	https://doi.org/10.1016/s0140-6736(21)01442-2
Publication status	Published - 10 Jul 2021

Bibliographical note

Funding Information:
TD-S declares no competing interests. DP-A's research group has received research grants from the European Medicines Agency, the Innovative Medicines Initiative, Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, AstraZeneca, and UCB Biopharma, all outside of the area of work commented on here.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s0140-6736(21)01442-2

http://www.thelancet.com/article/S0140673621014422/pdf

Cite this

@article{ffb4fece642649b6b5bbfa0dc1a484f0,

title = "Heterologous vaccine regimens against COVID-19",

author = "Talita Duarte-Salles and Daniel Prieto-Alhambra and {Prieto Alhambra}, {D. (Dani)}",

note = "Funding Information: TD-S declares no competing interests. DP-A's research group has received research grants from the European Medicines Agency, the Innovative Medicines Initiative, Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, AstraZeneca, and UCB Biopharma, all outside of the area of work commented on here.",

year = "2021",

month = jul,

day = "10",

doi = "10.1016/s0140-6736(21)01442-2",

language = "English",

volume = "398",

pages = "94--95",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10295",

}

TY - JOUR

T1 - Heterologous vaccine regimens against COVID-19

AU - Duarte-Salles, Talita

AU - Prieto-Alhambra, Daniel

AU - Prieto Alhambra, D. (Dani)

N1 - Funding Information: TD-S declares no competing interests. DP-A's research group has received research grants from the European Medicines Agency, the Innovative Medicines Initiative, Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, AstraZeneca, and UCB Biopharma, all outside of the area of work commented on here.

PY - 2021/7/10

Y1 - 2021/7/10

UR - http://www.scopus.com/inward/record.url?scp=85109456209&partnerID=8YFLogxK

U2 - 10.1016/s0140-6736(21)01442-2

DO - 10.1016/s0140-6736(21)01442-2

M3 - Comment/Letter to the editor

AN - SCOPUS:85109456209

SN - 0140-6736

VL - 398

SP - 94

EP - 95

JO - The Lancet

JF - The Lancet

IS - 10295

ER -

Heterologous vaccine regimens against COVID-19

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this